NYXH Nyxoah

Publication relating to transparency notifications

Publication relating to transparency notifications

                

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), September 5, 2025, 10:30 pm CET / 4:30 pm ET In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

On September 4, 2025, Nyxoah received a transparency notification from Cochlear Limited and Cochlear Investments Pty Ltd following a passive crossing of a threshold. Based on the notification, Cochlear Investments Pty Ltd holds 5,631,319 voting rights, representing 14.999% of the total number of voting rights on August 29, 2025 (37,544,782).

The notification dated September 4, 2025 contains the following information:

  • Reason for the notification: passive crossing of a threshold
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • Cochlear Limited (with address at 1 University Avenue, Macquarie University, NSW 2109, Australia)
    • Cochlear Investments Pty Ltd (with address at 1 University Avenue, Macquarie University, NSW 2109, Australia)
  • Date on which the threshold was crossed: August 29, 2025
  • Threshold that is crossed: 15%
  • Denominator: 37,544,782
  • Notified details:



A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
Cochlear Limited0000.00%0.00%
Cochlear Investments Pty Ltd3,947,6175,631,319015.00%0.00%
Subtotal3,947,6175,631,319  15.00% 
 TOTAL5,631,319 015.00%0.00%
  • Full chain of controlled undertakings through which the holding is effectively held: Cochlear Investments Pty Ltd is a wholly owned subsidiary of Cochlear Limited, which is listed on the Australian Securities Exchange and has no controlling shareholder.
  • Additional information: This notification concerns a downward crossing of the 15% threshold following a passive decrease, whereby Cochlear Investments Pty Ltd’s holding in Nyxoah fell from 15.04% to 14.999% of the voting rights.

*

* *

Contact:

Nyxoah

John Landry, CFO



Attachment



EN
05/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

Nyxoah Présente les Dernières Avancées Concernant son Expansion au Moy...

Nyxoah Présente les Dernières Avancées Concernant son Expansion au Moyen-Orient Nyxoah Présente les Dernières Avancées Concernant son Expansion au Moyen-Orient De nouveaux centres à Dubaï, au Koweït et à Abu Dhabi après la première implantation de Genio® dans la région au début de l'année 2025 Mont-Saint-Guibert, Belgique – 23 septembre 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neurom...

 PRESS RELEASE

Nyxoah Provides an Update on Expanded Middle East Presence

Nyxoah Provides an Update on Expanded Middle East Presence Nyxoah Provides an Update on Expanded Middle East Presence New Centers in Dubai, Kuwait, and Abu Dhabi Following First Genio® Implant in the Region Earlier in 2025 Mont-Saint-Guibert, Belgium – September 23, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced the continued expansion of its commercial footprint in the Middle East, following the first successful Genio® implant in A...

 PRESS RELEASE

Nyxoah Entame une Procédure Judiciaire pour Violation de Brevets Contr...

Nyxoah Entame une Procédure Judiciaire pour Violation de Brevets Contre Inspire Medical Systems, Inc. Nyxoah Entame une Procédure Judiciaire pour Violation de Brevets Contre Inspire Medical Systems, Inc. Mont-Saint-Guibert, Belgique – 15 septembre 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui avoir entamé une procédure judiciaire contre Inspire Medi...

 PRESS RELEASE

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Syste...

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. Mont-Saint-Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) and Nyxoah, Inc. (collectively, “Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that it has filed a lawsuit against Inspire Medical Systems, Inc. (“Inspire”) alleging that the Inspire IV and Inspire V device...

 PRESS RELEASE

Publication relating to transparency notifications

Publication relating to transparency notifications                  REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 5, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. On September 4, 2025, Nyxoah received a transparency notification from Cochlear Limited and Cochlear Investments Pty Ltd following a passive crossing of a thresh...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch